Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenza Borin

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Mediterranean Journal of Hematology and Infectious Diseases|May 3, 2012
A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of LiteratureElena Elli, Caterina Cecchetti, Angelo Belotti, et al.
Leukemia Research|December 2, 2014
Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complicationsAngelo Belotti, Lorena Duca, Lorenza Borin, et al.
Blood Reviews|April 28, 2018
Iron toxicity - Its effect on the bone marrowAlessandro Isidori, Lorenza Borin, Elena Elli, et al.
Leukemia Research|June 2, 2022
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experienceCarolina Steidl, Andrea Aroldi, Luca Mologni, et al.
Platelets|December 6, 2024
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experienceMonica Carpenedo, Arianna Zappaterra, Lorenzo Del Castello, et al.
Leukemia Research|August 3, 2013
Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica Lombarda"Alfredo Molteni, Marta Riva, Annamaria Pellizzari, et al.
Scientific Reports|January 29, 2021
Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopeniaIrene Motta, Dario Consonni, Marina Stroppiano, et al.
The Oncologist|May 22, 2024
Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective studyBeatrice Manghisi, Lorenza Borin, Maria Rosaria Monaco, et al.
American Journal of Hematology|November 16, 2012
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patientsBarbara Scappini, Giacomo Gianfaldoni, Francesco Caracciolo, et al.
Leukemia Research|February 8, 2016
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"Alfredo Molteni, Marta Riva, Lorenza Borin, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Mediterranean Journal of Hematology and Infectious Diseases|May 3, 2012
A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of LiteratureElena Elli, Caterina Cecchetti, Angelo Belotti, et al.
Leukemia Research|December 2, 2014
Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complicationsAngelo Belotti, Lorena Duca, Lorenza Borin, et al.
Blood Reviews|April 28, 2018
Iron toxicity - Its effect on the bone marrowAlessandro Isidori, Lorenza Borin, Elena Elli, et al.
Leukemia Research|June 2, 2022
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experienceCarolina Steidl, Andrea Aroldi, Luca Mologni, et al.
Platelets|December 6, 2024
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experienceMonica Carpenedo, Arianna Zappaterra, Lorenzo Del Castello, et al.
Leukemia Research|August 3, 2013
Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica Lombarda"Alfredo Molteni, Marta Riva, Annamaria Pellizzari, et al.
Scientific Reports|January 29, 2021
Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopeniaIrene Motta, Dario Consonni, Marina Stroppiano, et al.
The Oncologist|May 22, 2024
Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective studyBeatrice Manghisi, Lorenza Borin, Maria Rosaria Monaco, et al.
American Journal of Hematology|November 16, 2012
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patientsBarbara Scappini, Giacomo Gianfaldoni, Francesco Caracciolo, et al.
Leukemia Research|February 8, 2016
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"Alfredo Molteni, Marta Riva, Lorenza Borin, et al.
Pageof 3